Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Radiographically documented metastatic disease with evidence of disease progression Laboratory parameters per protocol~* Surgically or medically castrate~* Patients who have progressed following:~* a. at least initial therapy (chemotherapy or treatment with a hormonal agent known to impact survival such as abiraterone and enzalutamide); or~* b. one first-line chemotherapy regimen and one additional hormonal agent known to impact survival such as abiraterone and enzalutamide; or~* c. failure of two lines of chemotherapy; or~* d. failure of pre-chemotherapy abiraterone or enzalutamide and subsequent chemotherapy~Exclusion Criteria:~* Patients with neuroendocrine or small cell cancer of the prostate 2. History of other malignant disease (with the exception of the primary prostate cancer and non-melanoma skin tumors) in the past 5 years Pre-defined co-morbidities~* Administration of experimental therapy within the last 4 weeks before start of screening~* Treatment with immunotherapy within the last 3 months before start of screening~* Treatment with radiopharmaceutical drugs within 8 weeks before start of screening~* Receipt of oncolytic virus treatment or vaccination with a live virus within 4 weeks of study start~* History of organ transplantation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCVac and ONCOS-102 (Type: EXPERIMENTAL): ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).